Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)

AIMS: Little is known about the impact of sodium glucose co‐transporter 2 (SGLT2) inhibitors on cardiac biomarkers, such as natriuretic peptides, in type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF). We compared the effect of canagliflozin with glimepiride, based on changes...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ESC Heart Fail
Egile Nagusiak: Tanaka, Atsushi, Hisauchi, Itaru, Taguchi, Isao, Sezai, Akira, Toyoda, Shigeru, Tomiyama, Hirofumi, Sata, Masataka, Ueda, Shinichiro, Oyama, Jun‐ichi, Kitakaze, Masafumi, Murohara, Toyoaki, Node, Koichi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Original Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7373938/
https://ncbi.nlm.nih.gov/pubmed/32349193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12707
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak